The Latest Breaking News from IBD

Investors are more bullish on the outlook for the U.S. economy, even as noninvestors remain in a deep funk, the new IBD/TIPP Poll finds.

The Dow Jones fell Tuesday on Federal Reserve chair Jerome Powell's comments. Facebook-parent Meta climbed on more planned layoffs.

AztraZeneca (AZN), a U.K. developer of branded prescription therapeutics, ranks first in IBD's diversified medical industry group. But the Composite Rating is only 63. This, combined with the weakening of the market, makes this a solid choice for our familiar short iron condor. With the suspicion that the markets are…

The Dow Jones rose Friday after key economic data. AI stock leader C3.ai soared after the company's better-than-expected earnings.

"New" is intrinsically exciting. The potential of something new feels limitless and captivating. In CAN SLIM, IBD's seven-point investing paradigm, N is for "new" and is a crucial element of how to buy stocks. It may mean a new product or service, new management, new stock price highs, or new…

Investors tired of pie-in-the-sky tech profits might look for more concrete returns. Infrastructure Capital Advisors' best ETFs offer options.

The stock market rally rebounded bullishly Thursday despite Treasury yields racing above 4% and Tesla retreating. C3.ai stock spiked late.

Welcome to IBD Live! This list of FAQs and useful links will speed your learning curve. Some users have reported the inability to access the IBD Live show page on investors.com from their mobile and tablet devices. Please clear your browser cache and relaunch the browser to resolve this issue.…

A newly formed pattern may offer a new buying opportunity. Shares are up more than 20% this year.